Đặc điểm bộc lộ PD-L1 trong ung thư biểu mô tuyến dạ dày

Gastric cancer is the third most common cancer and the third leading cause of cancer-related death in Vietnam. Anti PD-1 and anti PD-L1 monoclonal antibodies, called immune checkpoint inhibitors, have shown promise in patients with gastric cancer. Our study is to assess the expression of PD-L1 on gastric adenocarcinoma and the relationship with clinicopathological features. Tissue samples were collected from patients who underwent surgical resection for gastric cancer without preoperative chemotherapy at the Hanoi Oncology Hospital and Bach Mai Hospital, between October 1, 2020 and August 31, 2021. The expression of PD-L1 was detected via immunohistochemistry in 96 gastric adenocarcinoma samples, using Rabbit monoclonal antibody (73-10, Leica). Positive staining was defined as CPS ≥ 1. The result is that about 38.5% of gastric adenocarcinoma tissues showed positive PD-L1 immunolabeling. There was no correlation between PD-L1 and age, sex, tumor location, tumor size, tumor differentiation of patients, vascular invastion and perineural invasion (p > 0.05). However, PD-L1 was significantly correlated to lymph node metastasis and the deepth of tumor invastion (p < 0.05).